Sanofi–Translate_Bio_COVID-19_vaccine

Sanofi–Translate Bio COVID-19 vaccine

Sanofi–Translate Bio COVID-19 vaccine

Vaccine candidate against COVID-19


The Sanofi–Translate Bio COVID-19 vaccine, also known as MRT5500 or VAW00001, was a COVID-19 vaccine candidate developed by Sanofi Pasteur and Translate Bio.[2][3] The development was stopped in September 2021.[4]

Quick Facts Vaccine description, Target ...

History

In June 2020, Sanofi, after lagging behind its competitors, "accelerated" the development of the vaccine via the smaller biotech firm Translate Bio, with a US$425 million partnership.[5]

Development of the vaccine halted in September 2021, with Sanofi citing the difficulty of running placebo-controlled studies with other mRNA vaccines (such as Pfizer's and Moderna's) already on the market. Despite this, the company reported "promising results" in its initial trials.[4]Sanofi has continued testing its recombinant protein vaccine, developed collaboratively with GlaxoSmithKline, to serve as a booster dose for other COVID-19 vaccines.[4]


References

  1. Abboud L (28 September 2021). "Sanofi stops development of Covid vaccine based on mRNA technology". Financial Times.
  2. "Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate". Sanofi. 12 March 2021. Archived from the original on 9 October 2021. Retrieved 20 March 2021.
  3. "Sanofi drops plans for messenger RNA vaccine against virus". Associated Press. 28 September 2021. Archived from the original on 14 October 2021. Retrieved 7 October 2021.
  4. Branswell H, Feuerstein A (23 June 2020). "Sanofi, a straggler in the Covid-19 vaccine race, accelerates its plans". STAT. Archived from the original on 20 October 2021. Retrieved 7 August 2020.

Share this article:

This article uses material from the Wikipedia article Sanofi–Translate_Bio_COVID-19_vaccine, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.